The question of whether “felon” will be another moniker attached to Martin Shkreli, a former pharmaceutical executive standing trial for securities and wire fraud who has been given the tongue-in-cheek nickname “Pharma Bro,” was placed July 28 in the hands of a federal jury in Brooklyn.
While better known as the man responsible for increasing the price of an antiparasitic drug by 5,000 percent, Shkreli is accused of running a form of Ponzi scheme in which he defrauded investors into two hedge funds he created and paid them back by misappropriating $11 million in assets from Retrophin, which he also founded.
